Since the initial Children ́s Oncology Group trial employing crizotinib, the first ALK TKI to be FDA approved, in pediatric ALK positive cancers26 several neuroblastoma patients responding to ALK TKI treatment have been reported38,44. The gene discussed is ALK; the disease is neuroblastoma.